AR049065A1 - Forma de administracion para la contracepcion hormonal - Google Patents

Forma de administracion para la contracepcion hormonal

Info

Publication number
AR049065A1
AR049065A1 ARP050102210A ARP050102210A AR049065A1 AR 049065 A1 AR049065 A1 AR 049065A1 AR P050102210 A ARP050102210 A AR P050102210A AR P050102210 A ARP050102210 A AR P050102210A AR 049065 A1 AR049065 A1 AR 049065A1
Authority
AR
Argentina
Prior art keywords
contain
administration
hormones
folic acid
hormonal contraception
Prior art date
Application number
ARP050102210A
Other languages
English (en)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004026670A external-priority patent/DE102004026670A1/de
Priority claimed from DE102004026671A external-priority patent/DE102004026671A1/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR049065A1 publication Critical patent/AR049065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Forma de administracion para la anticoncepcion hormonal que comprende una cantidad determinada de unidades diarias, que contienen hormonas y una cantidad determinada de unidades diarias que no contienen hormonas, para la administracion oral diaria ininterrumpida, donde las unidades diarias que contienen hormonas contienen, cada una, un máximo de 200 mg. de ácido folico y las unidades diarias que no contienen hormonas contienen de mayor 200 mg. hasta la cantidad máxima de ácido folico admitida para mujeres de ácido folico.
ARP050102210A 2004-05-28 2005-05-27 Forma de administracion para la contracepcion hormonal AR049065A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004026670A DE102004026670A1 (de) 2004-05-28 2004-05-28 Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A DE102004026671A1 (de) 2004-05-28 2004-05-28 Darreichungsform zur hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
AR049065A1 true AR049065A1 (es) 2006-06-21

Family

ID=34969970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102210A AR049065A1 (es) 2004-05-28 2005-05-27 Forma de administracion para la contracepcion hormonal

Country Status (9)

Country Link
EP (2) EP1755562B1 (es)
AR (1) AR049065A1 (es)
DK (1) DK1755562T3 (es)
ES (1) ES2438734T3 (es)
PE (1) PE20060318A1 (es)
PL (1) PL1755562T3 (es)
PT (1) PT1755562E (es)
SI (1) SI1755562T1 (es)
WO (1) WO2005115349A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053771A1 (de) 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption
JP2009542588A (ja) * 2006-07-06 2009-12-03 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 避妊及び先天的異常の危険性の予防のための医薬製剤
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
ME03728B (me) 2015-06-18 2021-01-20 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888631A (en) * 1959-02-24 1962-01-31 Upjohn Co Improvements in or relating to oral therapeutic compositions comprising steroids
EP2002839A1 (en) 1998-04-17 2008-12-17 Ortho McNeil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6911438B2 (en) * 2001-09-12 2005-06-28 Jonathan V. Wright Hormone replacement formulation

Also Published As

Publication number Publication date
PE20060318A1 (es) 2006-06-15
ES2438734T3 (es) 2014-01-20
DK1755562T3 (da) 2013-12-16
PT1755562E (pt) 2013-12-26
SI1755562T1 (sl) 2014-02-28
EP1755562A1 (de) 2007-02-28
EP2263659A1 (de) 2010-12-22
EP1755562B1 (de) 2013-10-09
WO2005115349A1 (de) 2005-12-08
PL1755562T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
AR049065A1 (es) Forma de administracion para la contracepcion hormonal
RS54398B1 (en) THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
AR051397A1 (es) Composicion farmaceutica
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
UY27789A1 (es) Metodos y modalidades de dosificación para la liberación controlada de oxicodona.
UY25544A1 (es) Forma de dosificación de nefazodona
CL2008003446A1 (es) Protesis dental que comprende dientes y una base de protesis dental que consiste en dos porciones acrilicas que incluyen una plantilla con una primera porcion acrilica unida a los dientes y una segunda porcion con la forma del reborde edentado del paciente contigua a la primera porcion, para formara la protesis en una sola visita.
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
ATE541562T1 (de) Ibuprofen-suspension
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
ATE363840T1 (de) Capsaicinoid enthaltende pharmazeutische zusammensetzung zur oralen verabreichung
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
DK1615632T3 (da) Flydende orale formularer for kontrolleret udskillelse af betain
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PL1638582T3 (pl) Zastosowanie kwasu hialuronowego do wytwarzania środków do leczenia nawracających aft w jamie ustnej
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
AR065971A1 (es) Nuevo regimen de drosperinona/17beta-estradiol, producto farmaceutica combinado y conjunto de elementos (kit) para su aplicacion
ATE455540T1 (de) Orale dosierform für die kontrollierte arzneimittelfreisetzung

Legal Events

Date Code Title Description
FB Suspension of granting procedure